TY - JOUR T1 - Multicenter COPD registry for quality improvement and comparative effectiveness research JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P2727 AU - Jerry A. Krishnan AU - David H. Au AU - Shannon S. Carson AU - Todd A. Lee AU - Peter K. Lindenauer AU - MaryAnn A. McBurnie AU - Richard A. Mularski AU - Edward T. Naureckas AU - William M. Vollmer Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P2727.abstract N2 - RATIONALE: Studies evaluating quality, safety, effectiveness, and costs of care using registries linking Electronic Health Records from diverse healthcare settings are attracting increasing interest because they can provide information more applicable to 'real-world' patients and clinicians. METHODS: The COPD Outcomes-based Network for Clinical Effectiveness and Research Translation (CONCERT) developed a multicenter COPD registry (COPD DataHub) linking 8 U.S. academic healthcare institutions. Inclusion criteria were based on age (>40 yrs), ICD-9 billing codes, problem lists, medications, or spirometry from 2006 to 2010. The prevalence of Charlson comorbid conditions was estimated. An in-person study visit was used to collect additional information, including height, weight, smoking status, symptoms, and lung function. Preliminary findings are presented here. RESULTS: In 226,261 patients, the five most common co-morbid conditions (hospital and outpatient encounters) were diabetes (32 and 23%), heart failure (26 and 11%), renal disease (20 and 9%), malignancy (20 and 12%), and peripheral vascular disease (16 and 8%). In 1,216 patients who completed the study visit, 73% were overweight or obese, 84% were ever smokers, 44% smoked >40 pack-years, 34% had chronic bronchitis symptoms, and 54% had fixed airflow obstruction (post-BD FEV1/FVC<70%). CONCLUSIONS: Quality improvement and comparative effectiveness research in COPD should 1) include lung function testing to confirm the diagnosis, and 2) address a range of comorbid conditions, including overweight or obese body habitus and smoking-related behaviors. Given the high levels of comorbidity, heterogeneous treatment effects appear likely. ER -